Bengaluru/Chandigarh (Media Bureau) Centre has permitted HCG Cancer Hospital to commence the clinical trial to evaluate safety and efficacy of Convalescent Plasma therapy to treat COVID 19 patients.
HCG cancer hospital has received grant from Directorate General of Healthcare Services (DGHS), under the provisions of New Drugs and Clinical Trial Rules, 2019 to begin clinical trial of proposed Convalescent Plasma Therapy, according to a release here on Tuesday.
Convalescent Plasma Therapy is an experimental procedure for COVID-19 patients. In this treatment, plasma from a COVID-19 patient who has recovered from the disease is transfused into a Coronavirus patient who is in critical condition. Passive antibody therapy, through transfusion of convalescent plasma, may prevent clinical infection or blunt clinical severity in individuals with recent pathogen exposure.
